APA (7th ed.) Citation

Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, & Shenghai Xing. (2022). Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, and Shenghai Xing. Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Bo Shi, et al. Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Frontiers Media S.A., 2022.